BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 17709149)

  • 1. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
    Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study.
    Urbano TG; Clark CH; Hansen VN; Adams EJ; Miles EA; Mc Nair H; Bidmead AM; Warrington J; Dearnaley DP; Harmer C; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):58-63. PubMed ID: 17904235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma.
    Lee SW; Back GM; Yi BY; Choi EK; Ahn SD; Shin SS; Kim JH; Kim SY; Lee BJ; Nam SY; Choi SH; Kim SB; Park JH; Lee KK; Park SH; Kim JH
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):152-60. PubMed ID: 16472934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.
    Studer G; Huguenin PU; Davis JB; Kunz G; Lütolf UM; Glanzmann C
    Radiat Oncol; 2006 Mar; 1():7. PubMed ID: 16722599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
    Milano MT; Vokes EE; Kao J; Jackson W; List MA; Stenson KM; Witt ME; Dekker A; MacCracken E; Garofalo MC; Chmura SJ; Weichselbaum RR; Haraf DJ
    Int J Oncol; 2006 May; 28(5):1141-51. PubMed ID: 16596230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute toxicities experienced during simultaneous integrated boost intensity-modulated radiotherapy in head and neck cancers--experience from a north Indian regional cancer centre.
    Chakraborty S; Ghoshal S; Patil V; Oinam A; Suresh S
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):676-86. PubMed ID: 19748768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI
    Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
    Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
    Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.